Actinogen Medical Ltd
ACW
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 10.70 | 0.12% |
| CAC 40 | 8,352.86 | 12.15 | 0.15% |
| DAX 40 | 24,649.39 | 244.19 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,418.76 | 10.09 | -0.10% |
| HKSE | 23,412.18 | 75.90 | 0.33% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 69,174.97 | 613.41 | -0.88% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,808.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,110.81 | 4.56 | 0.11% |